The effects of pharmacist interventions on health outcomes in patients with advanced prostate cancer in Brazil

Autor(es)

Patricia M Aguiar ^[1] ; Ana Luiza PM Mori ^[2] ; Maria GF de Lima ^[3] ; Magali SPN Rossi ^[4] ; Maria Aparecida Nicoletti ^[5] ; Karina OF Martins ^[6] ; Ana Lúcia M Lopes ^[7] ; Teresa Cristina M Coan ^[8] ; Oscar Eduardo H Fugita ^[9] ; Sílvia Storpirtis ^[10]

Afiliação do(s) autor(es)

^[1] University of São Paulo. School of Pharmaceutical Sciences - Brasil

^[2] University of São Paulo. School of Pharmaceutical Sciences - Brasil

^[3] University of São Paulo. School of Pharmaceutical Sciences - Brasil

^[4] University of São Paulo. School of Pharmaceutical Sciences - Brasil

^[5] University of São Paulo. School of Pharmaceutical Sciences - Brasil

^[6] Secretariat of Health of the State of Sao Paulo - Brasil

^[7] University of São Paulo. Teaching Hospital - Brasil

^[8] University of São Paulo. Teaching Hospital - Brasil

^[9] University of São Paulo. Teaching Hospital - Brasil

^[10] University of São Paulo. School of Pharmaceutical Sciences - Brasil

• Tipo de documento: Artigo Científico
• Fonte: Brazilian Journal of Pharmaceutical Sciences; v. 58, 2022-04-22.

Resumo

Abstract This study examined the effects of pharmacist interventions for patients with advanced prostate cancer. A pre-post study was conducted between October 2014 and August 2017 in a community pharmacy in Brazil for outpatients with advanced prostate cancer, aged ≥ 18 years, using cyproterone acetate and/or goserelin. The patients had face-to-face meetings with a pharmacist who dispensed antiandrogenic drugs and performed interventions aimed at solving and/or preventing drug-therapy problems. Primary outcomes regarding prostate-specific antigen (PSA) and testosterone levels were compared at 0, 6, and 12 months, whereas secondary outcomes-medication adherence and quality of life-were compared at baseline and at the 12-month follow-up. Medication adherence was assessed using the Morisky-Green test, and quality of life was measured by the Medical Outcomes Study 36-item Short Form (SF-36) and the Functional Assessment of Cancer Therapy-Prostate (FACT-P). The analysis included 20 patients; 311 drug-therapy problems were identified and most of them were related to adverse reactions (78.5%). The most common adverse reactions were reduced libido, erectile dysfunction, hyperglycemia, fatigue, and gynecomastia. Testosterone levels significantly decreased at 6 months, and PSA levels at 6 and 12 months. No significant changes in adherence were noted at the end of the study. A significant increase in the “pain” domain and an improvement trend in the “physical aspects” and “vitality” domains were observed based on the SF-36 instrument. The findings show that pharmacist interventions were able to improve PSA and testosterone levels, and some domains of quality of life of patients. (AU)

• Processo FAPESP: 12/51707-4 - Seguimento farmacoterapêutico de pacientes na farmácia universitária da USP: pesquisa clínica fase IV, avaliação e proposição de mecanismos de enfrentamento da judicialização na área de medicamentos no Brasil em parceria com a Secretaria de Estado da Saúde de São Paulo
• Beneficiário: Silvia Storpirtis
• Modalidade de apoio: Auxílio à Pesquisa - Pesquisa em Políticas Públicas para o SUS